This company has been acquired
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Taisho Pharmaceutical Holdings Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Taisho Pharmaceutical Holdings has a total shareholder equity of ¥857.3B and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥1,005.5B and ¥148.2B respectively. Taisho Pharmaceutical Holdings's EBIT is ¥18.9B making its interest coverage ratio -4. It has cash and short-term investments of ¥266.4B.
Anahtar bilgiler
0%
Borç/özkaynak oranı
JP¥0
Borç
| Faiz karşılama oranı | -4x |
| Nakit | JP¥266.37b |
| Eşitlik | JP¥857.30b |
| Toplam yükümlülükler | JP¥148.17b |
| Toplam varlıklar | JP¥1.01t |
Son finansal sağlık güncellemeleri
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: TAIS.F's short term assets (¥416.8B) exceed its short term liabilities (¥80.8B).
Uzun Vadeli Yükümlülükler: TAIS.F's short term assets (¥416.8B) exceed its long term liabilities (¥67.3B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: TAIS.F is debt free.
Borcun Azaltılması: TAIS.F has not had any debt for past 5 years.
Borç Kapsamı: TAIS.F has no debt, therefore it does not need to be covered by operating cash flow.
Faiz Kapsamı: TAIS.F has no debt, therefore coverage of interest payments is not a concern.